Targeted Medical Pharma Inc.

See/shell Biotechnology, Inc.

The Upjohn Co.

Bio Technology, LLC

Beverly Glen Medical Systems, LLC

Immudx, Inc.

William E Shell

Elizabeth Charuvastra

Jackie R See

Timothy Donald Callahan

Michael H Burnam

Zoltan A Tokes

A system for submitting a claim for a dispensed medication to a patient by a point-of-care physician including means acquiring at least one of the group consisting of a national practitioner number and a non pharmacy dispensing number for the point-of-care physician; means for displaying to a user a selection of data fields relating to the claim; means for inputting into the data fields data relating to the claim including the at least one of the group consisting of the national practitioner identifier number and the non pharmacy dispensing number; means for transmitting to a logic switch the claim containing the at least one of the group consisting of a national practitioner identifier number and a non pharmacy dispensing number identifying the point-of-care physician for determining the processor for the claim; means for determining the pathway for the claim based on a type of payor associated with the patient; means for processing the claim containing the at least one of the group consisting of a national practitioner identifier number and a non pharmacy dispensing number to identify the point-of-care physician; and responsive to the means for processing, means for transmitting to the point-of-care physician an adjudication regarding the claim.

System and method for submitting medication claims by point-of-care physicians

The methods and compositions for potentiating pharmaceuticals with amino acid based medical foods provides improved cognitive function; induced and maintained sleep; reduced pain, inflammation, blood pressure, anxiety, asthma, duration of viral infection, insulin resistance, and appetite; and treated depression. The amino acid based medical foods, co-packed with at least one selected pharmaceutical, potentiate the pharmaceutical by enhancing the production of neurotransmitters through the oral administration of neurotransmitter precursors, along with natural plant and animal substances that stimulate uptake of the neurotransmitter precursors, cause release of neurotransmitters, cause disinhibition of the neuronal brake, and activate adenylate cyclase in order to avoid tachyphylaxis and prevent pharmacologic tolerance.

Method and compositions for potentiating pharmaceuticals with amino acid based medical foods

This invention describes a method and composition to enhance the synthesis and release of the neurotransmitters by the oral administration of neurotransmitter precursors, along with natural plant substances that stimulate uptake of the neurotransmitters precursors, while adding natural plant substances that activate adenylate cyclase in order to avoid attenuation and prevent pharmacologic tolerance. The invention describes compositions for a medical foods that are designed to improve cognitive function, induced sleep, a improve Parasympathetic function, improve autonomic balance, increase nitric oxide production, reduce blood pressure, increase blood flow, and treat virus infections. The compositions include amino acids such as choline, herbs such ginkgo biloba, and other foods such as coca. The invention also describes the use of physiologic tests such as 24 hour ECG monitoring to create the appropriate combinations and assess the useful proportions.

Composition and method to augment and sustain neurotransmitter production

This invention describes a method and composition to enhance the synthesis and release of the neurotransmitters by the oral administration of neurotransmitter precursors, along with natural plant substances that stimulate uptake of the neurotransmitters precursors, while adding natural plant substances that activate adenylate cyclase in order to avoid attenuation and prevent pharmacologic tolerance. The invention describes compositions for a medical foods that are designed to improve cognitive function, induced sleep, a improve Parasympathetic function, improve autonomic balance, increase nitric oxide production, reduce blood pressure, increase blood flow, and treat virus infections. The compositions include amino acids such as choline, herbs such, and other foods such as coca. The invention also describes the use of physiologic tests such as 24 hour ECG monitoring to create the appropriate combinations and assess the useful proportions.

A method and composition to enhance the synthesis and release of the neurotransmitters by the oral administration of neurotransmitter precursors, along with natural plant substances that stimulate uptake of the neurotransmitters precursors, while adding natural plant substances that activate adenylate cyclase in order to avoid attenuation and prevent pharmacologic tolerance. The compositions for medical foods are designed to improve cognitive function, induced sleep, improve Parasympathetic function, improve autonomic balance, increase nitric oxide production, reduce blood pressure, increase blood flow, and treat virus infections. The compositions include amino acids such as choline, herbs such ginkgo biloba, and other foods such as cocoa. The method uses physiologic tests such as 24 hour ECG monitoring to create the appropriate combinations and assess the useful proportions.

A quantitative method and apparatus for measuring a cardiac function interval. Beat-to-beat data representative of a cardiac interval is collected over an extended period of time. A series of bins, each of which has a defined value range, is defined. The collected data is organized into the bins in accordance with the value of the data and the value range of the bin. The percentage of data in each bin may be calculated based upon the quantity of data in each bin.

Quantitative method and apparatus for measuring QT intervals from ambulatory electrocardiographic recordings

The invention relates to an inexpensive and easy to use method of visualizing an arterial circulation, using biodegradable microspheres which are permeated with an imaging energy absorbent contrast material, such as an X-ray absorbent material, which enables the diagnosis of pulmonary embolism. The microspheres may be comprised of a variety of materials, including human albumin, and may be dyed with a number of X-ray absorbent materials, or other imaging energy absorbent materials. The microspheres are injected into the bloodstream at a particular location such that they travel through the desired circulation, e.g. an arterial circulation and ultimately become lodged in the capillaries of a tissue of interest. Upon exposure of the arterial circulation to X-rays, blood vessels therein containing the microspheres will absorb the X-rays, causing them to show on a developed X-ray film in contrast to other blood vessels and body tissue which do not contain the microspheres that transmit the X-rays. The microspheres are designed to dissolve into the bloodstream within fifteen to thirty minutes after their introduction, the X-ray dye or other contrast material being ultimately excreted from the body via the urine or metabolized by the liver.

Use of biodegradable microspheres labeled with imaging energy constrast

A kit for preventing or treating arterial dysfunction resulting from an angioplasty procedure and particularly, in myocardial angioplasty procedures in human beings. The kit provides the materials necessary to introduce a selected amount of an intraarterial prostaglandin compound into an artery, such as a coronary artery, in which an angioplasty procedure is to occur and an intravenous prostaglandin compound. The prostaglandin compound will provide cyto-protection and provide antithrombotic effects and antiplatelet effects and antispasmatic effects. A composition is also provided for reducing dysfunction in angioplasty procedures and comprises a selected amount of a carrier and a prostaglandin compound carried in a specified amount and which carrier does not alter the prostaglandin compound and releases the prostaglandin compound at a rate sufficient to dilate blood vessels to thereby produce the required efficacy. The kit is a prepackaged combination of components which provides for the complete administration of the prostaglandin compound before, during and after the angioplasty procedure.

Kit for preventing or treating arterial dysfunction resulting from

A method and a composition for accumulating and the binding of food fats in an animal body gastrointestinal tract. The method and composition rely upon non-biodegradable collagen particles, such as microspheres, having a size of at least two microns and a fat receptor, such as bile, capable of having food fat adhered thereto on the surface of the particles. These particles are sufficiently large so that they do not pass through the surface mucosa of the gastrointestinal tract and permit the particles with the food fat to pass through the gastrointestinal tract and out of the body through animal excretion.

Dietary fat reduction

A method for reducing dysfunction in angioplasty procedures and particularly, in myocardial angioplasty procedures in human beings is desired. The method involves the introduction of a selected amount of intra-arterial prostaglandin compound into an artery, such as a coronary artery, in which an angioplasty procedure is to occur. The prostaglandin compound will provide cyto-protection and provide antithrombotic effects and antiplatelet effects and antispasmatic effects. The prostaglandin compound is administered in a pharmacological amount, that is, an amount substantially greater than the prostaglandin which would be generated by a normal myocardial artery when insulated and thus, constitutes an administration substantially greater than an amount which would be administered in a replacement therapy. A composition is also provided for reducing dysfunction in angioplasty procedures and comprises a selected amount of a carrier and a prostaglandin compound carried in a specified amount and which carrier does not alter the prostaglandin compound and releases the prostaglandin compound at a rate sufficient to dilate blood vessels to thereby produce the required efficacy. A prepackaged combination of components provides for the complete administration of the prostaglandin compound before, during and after the angioplasty procedure.

Method and compositions for reducing dysfunction in angioplasty

A process for making a volumetric determination of the quantity of a fluid, such as a liquid, by evaluation of a small sample of that fluid. The method comprises labeling microspheres with a non-radioactive substance and introducing the labeled microspheres into a body of fluid for which a determination is to be made. The microspheres are allowed to disperse in the body of fluid. Thereafter, a sample of the fluid which is of know or measurable volume, is selected. The number of microspheres present in the sample is then determined, from which a calculation of the volumetric measurement of the fluid may be made. The process is also adaptable to measuring the flow rate of a moving stream of fluid, since volume is one of the parameters of flow rate, and is also adaptable to determine the percentages of fluid components present in a mixture thereof.

Volumetric determination of a fluid

A method and means for determining the risk of future cardiac ischemic events in a patient after a sentinel event in that same patient, wherein levels of acid glycoprotein and CK-MB are monitored relative to predetermined threshold levels, within a prescribed time frame after the sentinel event, and these monitored levels are then correlated with the predicted likelihood of future cardiac ischemic events to classify such cardiac patients into categories of risk.

Growing community of inventors

Los Angeles, CA, United States of America

William E Shell